Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SCD | O00767 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4171295 | 0.90 | MEN1 (0.35) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL4172815 | 0.87 | KDM4E (0.38) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL4161947 | 0.87 | PKM (0.36) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL4171348 | 0.82 | L3MBTL1 (0.32) | MEN1KMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4164764 | 0.82 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4161956 | 0.81 | MPO (0.31) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3753694 | 0.73 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| Bromide SCHEMBL5382542 | 0.72 | IDO1 (0.35) | MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL4169700 | 0.71 | MEN1 (0.36) | MEN1KMT2ASMN1; SMN2L3MBTL1CYP1A2 | |
| SCHEMBL2890776 | 0.70 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048112-A1 | Novel Herbicides | HAX1, MTX1, CYP4X1 | MEN1 1520/4885KMT2A 135/4885SMN1; SMN2 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.